Skip to main content
Brian Windsor

Brian Windsor

President and COO, Aileron Therapeutics
United States
Brian Windsor, Ph.D. has served as the President and Chief Operating Officer of Aileron since October 2023. Prior to becoming president and chief operating officer, Dr. Windsor served, since July 2013, as President, Chief Executive Officer and a Director of Lung Therapeutics. From September 2019 to March 2022, Dr. Windsor served as a Director and the Chief Science Officer of TFF Pharmaceuticals, Inc., a public biopharmaceutical company that Lung spun out into an independent company. From January 2018 to March 2022, Dr. Windsor provided consulting services to TFF Pharmaceuticals, Inc. in the areas of science and technology. From November 2009 to March 2013, Dr. Windsor served as president of Enavail, LLC, a specialty pharmaceutical manufacturing company, where he oversaw all aspects of the company’s pharmaceutical drug development. Before joining Enavail, Dr. Windsor directed portfolio company management for Emergent Technologies, Inc., an early stage technology venture creation and management company, where he served as managing director or president for ten portfolio companies. Dr. Windsor holds a B.S. and a Ph.D. in molecular biology from The University of Texas at Austin.

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.